• Some people with post-traumatic stress disorder (PTSD) report short-term relief from symptoms such as anxiety, sleep problems, and nightmares after using cannabis.
• Current clinical evidence does not establish cannabis as an effective treatment for PTSD, and the best available randomized trial found that active cannabis did not significantly outperform a placebo for overall PTSD symptoms.
• A small randomized trial of the synthetic cannabinoid nabilone found promising results for PTSD-related nightmares, but the study included only 10 participants and requires replication.
• Cannabis can cause adverse effects, including anxiety, impaired attention and memory, dependence, and cannabis use disorder (CUD).
• The 2023 U.S. Department of Veterans Affairs/Department of Defense (VA/DoD) clinical practice guideline recommends against using cannabis or cannabis derivatives to treat PTSD because of insufficient evidence of efficacy and known risks.
• Evidence-based psychotherapy and established medications remain the recommended first-line approaches to PTSD treatment.

Post-traumatic stress disorder can develop after experiencing or witnessing a traumatic event. Although PTSD is often associated with military combat, it can affect survivors of assault, abuse, serious accidents, disasters, and other traumatic experiences.

Psychotherapy is central to evidence-based PTSD treatment, with trauma-focused approaches generally receiving the strongest support. Medications may also be used depending on a patient’s symptoms and circumstances.

At the same time, cannabis has attracted considerable interest among people seeking relief from PTSD symptoms. Some patients report that cannabis helps them sleep, reduces anxiety, or temporarily makes distressing thoughts easier to manage. However, individual reports of symptom relief are different from evidence that a treatment safely and reliably improves PTSD.

Research examining cannabis and PTSD remains limited and sometimes conflicting. A 2024 systematic review concluded that the available studies vary considerably in quality and methodology, while randomized evidence has not demonstrated a clear overall PTSD treatment benefit. [1]

PTSD symptoms are generally organized into four major categories:

• Intrusion symptoms: unwanted memories, nightmares, flashbacks, or intense emotional reactions to reminders of the traumatic event.
• Avoidance: avoiding thoughts, feelings, people, places, or situations associated with the trauma.
• Negative changes in thoughts and mood: persistent negative emotions, detachment from others, difficulty experiencing positive emotions, or distorted beliefs about oneself or the traumatic event.
• Changes in arousal and reactivity: irritability, hypervigilance, exaggerated startle responses, concentration difficulties, and sleep disturbances.

PTSD can substantially interfere with relationships, employment, sleep, and everyday functioning.

Evidence-based treatments include trauma-focused psychotherapies and, when appropriate, medications. The VA/DoD clinical practice guideline emphasizes evidence-based PTSD treatments rather than cannabis because cannabis has not demonstrated sufficient efficacy in controlled clinical research. [2]

Complex PTSD (CPTSD) is recognized as a separate diagnosis in the World Health Organization’s ICD-11 classification. It includes the core features of PTSD along with persistent difficulties involving emotional regulation, negative self-concept, and relationships.

Cannabis research specifically targeting CPTSD is even more limited than research on PTSD. Consequently, findings from PTSD studies should not automatically be interpreted as evidence that cannabis effectively treats CPTSD.

Cannabis contains numerous compounds known as cannabinoids. The two most widely studied are delta-9-tetrahydrocannabinol (THC), which produces many of cannabis’s psychoactive effects, and cannabidiol (CBD).

Cannabinoids interact directly or indirectly with the body’s endocannabinoid system, which is involved in processes including stress responses, emotional learning, sleep, and memory. These mechanisms have led researchers to investigate whether cannabinoids could influence PTSD symptoms.

A biological rationale, however, does not prove that cannabis is an effective clinical treatment.

The VA’s National Center for PTSD notes that some people with PTSD use cannabis to relieve symptoms but concludes that research to date does not support cannabis as an effective PTSD treatment. [3]

Anxiety and hyperarousal are common PTSD symptoms. Cannabinoids, particularly CBD, have been investigated for possible anxiety-related effects.

Research suggests CBD may have anxiolytic properties under certain experimental conditions, but findings from general anxiety research cannot automatically be applied to PTSD. Appropriate doses, formulations, treatment duration, and long-term effects remain uncertain.

THC presents an additional complication because its effects can vary by dose and individual. While some users describe relaxation, THC can also produce or intensify anxiety, panic, paranoia, and cognitive impairment.

For that reason, describing cannabis broadly as an “anti-anxiety” PTSD treatment goes beyond what current clinical evidence supports.

Sleep disturbances and trauma-related nightmares are common in PTSD, and cannabinoids have been investigated as possible treatments.

One particularly interesting study examined nabilone, a synthetic cannabinoid rather than conventional plant cannabis. In a randomized, double-blind, placebo-controlled crossover trial involving 10 Canadian military personnel with PTSD, nabilone produced a greater reduction in recurring and distressing nightmare scores than placebo.[4]

The finding is promising but preliminary. The study’s extremely small sample means it cannot establish that cannabis generally treats PTSD-related nightmares.

Cannabis may also alter sleep architecture, and regular use can lead to tolerance or sleep difficulties during withdrawal. Therefore, evidence concerning short-term sleep effects should not be interpreted as proof of long-term therapeutic benefit.

The endocannabinoid system has attracted scientific interest because of its involvement in fear learning and fear extinction—the process through which a conditioned fear response becomes weaker when a previously threatening cue is repeatedly experienced without danger.

This has produced hypotheses that cannabinoids could potentially influence the processing of traumatic memories.

However, mechanistic and laboratory findings are not equivalent to evidence that cannabis helps patients successfully process trauma. More controlled clinical research is necessary before cannabinoids can be recommended for this purpose.

PTSD frequently occurs alongside depression and other mood symptoms, and some cannabis users report temporary improvements in mood.

Evidence is considerably less clear regarding sustained improvement. Cannabis can produce different psychological effects depending on THC concentration, CBD content, dose, frequency of use, individual vulnerability, and other factors.

Long-term or problematic cannabis use may also be associated with poorer mental health outcomes in some individuals. Cannabis therefore should not be characterized as an established mood-stabilizing treatment for PTSD.

The strongest evidence comes from controlled clinical trials rather than testimonials or observational reports.

A 2021 randomized, double-blind crossover trial evaluated smoked cannabis in 80 U.S. military veterans with PTSD. Participants received one of four preparations during the first treatment stage:

• high THC,
• high CBD,
• approximately equal THC and CBD, or
• placebo.

PTSD symptoms improved across all four groups during the three-week treatment period.

Crucially, however, none of the active cannabis preparations significantly outperformed placebo on the primary PTSD outcome during the placebo-controlled phase.[5]

The researchers concluded that additional, adequately powered controlled studies are necessary before determining whether smoked cannabis is an effective PTSD treatment.

This finding is important because symptom improvement after taking cannabis does not necessarily demonstrate that cannabis caused the improvement. Placebo effects, expectations, natural symptom fluctuations, concurrent treatment, and other factors can influence outcomes.

A 2024 systematic review examined studies of cannabis and cannabinoids across PTSD symptoms and symptom clusters. The evidence included observational research as well as a small number of randomized trials. [1]

Overall, findings were mixed, and studies with stronger experimental designs have not provided convincing evidence that cannabis improves overall PTSD symptoms.

The VA’s National Center for PTSD similarly notes that observational studies sometimes report improvement while randomized evidence is substantially less supportive. [3]

Cannabinoid research is not entirely negative.

As noted above, a small randomized crossover study found that nabilone improved PTSD-associated nightmares compared with placebo.[4] This suggests that specific cannabinoid medications targeting particular PTSD symptoms deserve further investigation.

It does not, however, establish that smoked cannabis, cannabis edibles, CBD products, or high-THC cannabis are effective treatments for PTSD generally.

Cannabis products vary dramatically in cannabinoid concentrations, potency, route of administration, and pharmacological effects.

Common categories include:

CBD-dominant products: These contain relatively high concentrations of cannabidiol and little THC. CBD is not intoxicating in the same manner as THC, but evidence supporting CBD as a PTSD treatment remains insufficient.

THC-dominant products: These produce stronger intoxicating effects. Although some users report improvements in sleep or distress, higher THC exposure can also increase anxiety, paranoia, cognitive impairment, and other adverse effects.

Balanced THC/CBD products: These contain meaningful concentrations of both cannabinoids. Researchers continue to investigate whether different cannabinoid ratios affect therapeutic outcomes and adverse effects.

Full-spectrum products: These contain multiple cannabinoids and other cannabis constituents. Claims that these products produce a clinically superior “entourage effect” for PTSD have not been established through high-quality clinical trials.

Cannabinoid content is considerably more relevant scientifically than broad commercial categories such as “indica” and “sativa.”

There is currently not enough clinical evidence to identify a specific cannabis strain as the best treatment for PTSD or CPTSD.

Popular strains are sometimes marketed or recommended online for relaxation, sleep, anxiety, or mood. However, these recommendations are generally based on consumer reports, product marketing, or individual experience rather than controlled PTSD trials.

Names such as Blue Dream, OG Kush, Granddaddy Purple, Northern Lights, or Jack Herer do not represent standardized medical formulations. Products sold under the same strain name may differ substantially in THC concentration, CBD concentration, terpene composition, and other characteristics.

Consequently, claims that a particular strain is clinically proven to treat PTSD should be viewed cautiously.

The traditional distinction between indica and sativa is also an unreliable basis for predicting medical effects.

Individual responses depend more on factors such as cannabinoid concentration, dose, route of administration, frequency of use, individual physiology, other medications, and previous cannabis exposure.

There is insufficient clinical evidence to recommend either “indica” or “sativa” as a superior PTSD treatment.

Cannabis is not risk-free, particularly when products contain substantial concentrations of THC or are used frequently.

Possible adverse effects include:

• increased anxiety or panic,
• paranoia,
• impaired attention and memory,
• dizziness,
• slowed reaction time,
• impaired judgment,
• tolerance,
• withdrawal symptoms, and
• cannabis use disorder.

The relationship between PTSD and problematic cannabis use is especially important. According to the VA’s National Center for PTSD, cannabis use disorder occurs disproportionately among veterans with PTSD, and chronic or problematic use may interfere with PTSD treatment outcomes in some patients. [3]

The VA also notes that evidence concerning long-term cannabis use and PTSD is mixed, with some studies finding temporary symptom relief without lasting improvement and others associating continued cannabis use with worse trauma-related symptoms. [3]

People using cannabis to self-manage PTSD should therefore discuss their use openly with a qualified healthcare professional, particularly when cannabis is being combined with psychiatric medications, alcohol, or other substances.

Current U.S. military and veteran clinical guidance is clear.

The 2023 VA/DoD Clinical Practice Guideline for the Management of PTSD and Acute Stress Disorder recommends against cannabis or cannabis derivatives for treating PTSD.[2]

The recommendation reflects:

• insufficient evidence demonstrating clinical efficacy,
• limited high-quality randomized trials,
• known adverse effects, and
• risks associated with problematic or long-term cannabis use.

The VA’s National Center for PTSD likewise states that current research does not support cannabis as an effective PTSD treatment. [3]

This does not mean cannabinoids have no potential therapeutic applications. Instead, it means that the evidence is currently insufficient to recommend cannabis as a PTSD treatment, particularly when better-supported therapies are available.

Cannabinoid research remains active.

Future studies may help determine whether specific cannabinoids, doses, formulations, or combinations can safely target particular PTSD symptoms such as nightmares, anxiety, or sleep disturbances.

Researchers also need larger randomized controlled trials with standardized products and longer follow-up periods. These studies will need to distinguish short-term symptom relief from meaningful, sustained improvement in PTSD.

The preliminary nabilone research illustrates why this distinction matters. A particular cannabinoid medication could eventually prove beneficial for a specific PTSD symptom even if whole-plant cannabis does not prove effective for PTSD overall.

Until stronger evidence becomes available, cannabis should be viewed as an experimental or inadequately established approach to PTSD treatment rather than a clinically proven replacement for evidence-based care.

Cannabis and cannabinoids are being studied for their potential effects on PTSD symptoms, and some people report short-term relief from anxiety, nightmares, sleep disturbances, or emotional distress.

However, the clinical evidence is substantially less conclusive than these personal reports might suggest.

The first randomized placebo-controlled trial of smoked cannabis for PTSD found that active cannabis preparations did not significantly outperform placebo during the controlled phase. [5] A 2024 systematic review likewise found mixed evidence and highlighted important limitations in the existing research. [1]

There are promising areas for further investigation. In particular, a small controlled study of the synthetic cannabinoid nabilone reported improvement in PTSD-related nightmares. [4] Larger trials are needed to determine whether such benefits are reproducible.

For now, major clinical guidance does not recommend cannabis as a PTSD treatment. Patients considering cannabis for PTSD symptoms should discuss potential benefits, risks, medication interactions, and evidence-based alternatives with a qualified healthcare professional.

Some people report temporary reductions in anxiety, nightmares, sleep problems, or other PTSD symptoms after using cannabis. However, controlled research has not established cannabis as an effective treatment for PTSD overall.[1][3][5]

No. Current evidence is insufficient to consider cannabis a scientifically established PTSD treatment. The first placebo-controlled trial of smoked cannabis found no significant advantage for active cannabis over placebo on the primary PTSD outcome.[5]

The 2023 VA/DoD clinical practice guideline recommends against cannabis and cannabis derivatives for treating PTSD.[2]

CBD has biological properties that make it an interesting research target, including possible effects on anxiety and fear processing. However, there is currently insufficient high-quality clinical evidence to recommend CBD as a treatment for PTSD.

Some patients report that THC-containing products reduce nightmares, but evidence for plant cannabis remains limited.

A small randomized trial found that nabilone, a synthetic cannabinoid related pharmacologically to THC, reduced PTSD-associated nightmares compared with placebo. Because the trial involved only 10 participants, larger studies are necessary.[4]

Potential risks include anxiety, paranoia, cognitive impairment, tolerance, dependence, withdrawal, and cannabis use disorder. Frequent or problematic cannabis use may also negatively affect PTSD symptoms or treatment outcomes in some individuals.[3]

No particular cannabis strain has been established through high-quality clinical research as an effective treatment for PTSD or CPTSD. Commercial strain names and indica/sativa classifications should not be interpreted as evidence-based medical recommendations.

Current evidence does not support replacing established PTSD treatments with cannabis. Evidence-based trauma-focused psychotherapy remains central to PTSD treatment, and medications may also be appropriate depending on the individual.

1. Rodas JD, George TP, Hassan AN. A systematic review of the clinical effects of cannabis and cannabinoids in posttraumatic stress disorder symptoms and symptom clusters. Journal of Clinical Psychiatry. 2024;85(1):23r14862. doi:10.4088/JCP.23r14862. PubMed PMID: 38353645.

2. U.S. Department of Veterans Affairs & U.S. Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. 2023.

3. Hill M, Loflin M, Hicks T, Browne K, Norman SB. Cannabis Use and PTSD Among Veterans. U.S. Department of Veterans Affairs, National Center for PTSD. Updated 2025.

4. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588. doi:10.1016/j.psyneuen.2014.11.002. PMID: 25467221.

5. Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLOS ONE. 2021;16(3):e0246990. doi:10.1371/journal.pone.0246990.